Abstract
Elucidating the pathogenesis of colon cancer, one of the commonest fatal malignancies in the Western world, represents an important challenge for biomedical science. The seminal observation that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the incidence of and mortality from colorectal cancer1 has ushered in a new approach to the study of colon cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Thun, M.J., Namboodiri, M.M., and Heath C., Jr. Aspirin use and reduced risk of fatal colon cancer. New Engl. J. Med. 325:1593–1596, 1991.
Smith, W.L., Garavito, R.M., and De Witt, D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-l and-2. J. Biol. Chemi. 271:33157–33160, 1996.
Levy, G.N. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J. 11:234–247, 1997.
Kutchera, W., Jones, D.A., Matsunami, N., et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc. Natl. Acad. Sci. USA 93:4816–4820, 1996.
Eberhart, C.E., Coffey, R.J., Radhika, A., Giardiello, F.M., Ferrenbach, S., and Dubois, R.N. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and carcinomas. Gastroenterol. 107:1183–1188, 1994.
Abramson, S.B. and Weissmann, G. The mechanisms of action of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 32:1–9, 1989.
Pines, J. Cyclins, CDKs, and cancer. Semin. Cancer Biol. 6:63–72, 1995.
Bayer, B., Kruth, H., Vaughn, M., and Beaven, M. Arrest of cultured cells in the G1 phase of the cell cycle by indomethacin. J. Pharmacol. Exp. Therap. 210:106–111, 1979.
Bayer, G. and Beaven, M. Evidence that indomethacin reversibly inhibits cell growth in the G1 phase of the cell cycle. Biochem. Pharmacol. 28:441–443, 1979.
Shiff, S.J., Tsai, L., Qiao, L., and Rigas, B. The effect of sulindac on cell proliferation and the cell cycle distribution of human colon cancer cells. Gastroenterol. 106:A440, 1994.
Shiff, S.J., Qiao, L., Tsai, L.-L., and Rigas, B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest. 96:491–503, 1995.
Shiff, S.J., Koutsos, M.I., Qiao, L., and Rigas, B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp. Cell Res. 222:179–188, 1996.
Piazza, G.A., Rahm, A.L.K., Krutzsch, M., et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 55:3110–3116, 1995.
Morgan, D.O. Principles of CDK regulation. Nature 374:131–134, 1995.
Sherr, C.J. Mammalian G1 cyclins. Cell 73:1059–1065, 1993.
Sherr, C.J. G1 phase progression: cycling on cue. Cell 79:551–555, 1994.
Maity, A., McKenna, W.G., and Muschel, R.J. The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother. Oncol. 31:1–13, 1994.
Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304–6311, 1991.
Shaw, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B., and Costa, J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA 89:4495–4499, 1992.
Fritsche, M., Haessler, C., and Brandner, G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8:307–318, 1993.
Leach, S.D., Scatena, C.D., Keefer, C.J., et al. Negative regulation of Weel expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis. Cancer Res. 58:3231–3236, 1998.
Winters, Z.E., Ongkeko, W.M., Harris, A.L., and Norbury, C.J. p53 regulates Cdc2 independently of inhibitory phosphorylation to reinforce radiation-induced G2 arrest in human cells. Oncogene 17:673–684, 1998.
Weinberg, R.A. The retinoblastoma protein and cell cycle control. Cell 81:323–330, 1995.
Waddell, W.R. and Loughry, R.W Sulindac for polyposis of the colon. J. Surg. Oncol 24:83–87, 1983.
Giardiello, F.M., Hamilton, S.R., Krush, A.J., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. New Engl. J. Med. 328:1313–1316, 1993.
Takayama, T., Katsuki, S., Takahashi, Y., et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. New Engl. J. Med. 339:1277–1284, 1998.
Goldberg, Y., Nassif, I.I., Pittas, A., et al. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: Alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 12:893–901, 1996.
Qiao, L., Shiff, S.J., and Rigas, B. Sulindac sulfide alters the expression of cyclin proteins in HT-29 colon adenocarcinoma cells. Int. J. Cancer 76:99–104, 1998.
Qiao, L., Shiff, S.J., and Rigas, B. Sulindac sulfide induces several subpopulations of colon cancer cells, defined by PCNA/Ki-67 and DNA strand breaks. Biochim. Biophys. Acta 1359:222–232, 1997.
Qiao, L., Shiff, S.J., and Rigas, B. Sulindac sulfide inhibits the proliferation of colon cancer cells—diminished expression of the proliferation markers PCNA and Ki-67. Cancer Lett. 115:229–234, 1997.
Herrmann, C., Block, C., Geisen, C., et al. Sulindac sulfide inhibits Ras signaling. Oncogene 17:1769–1776, 1998.
Bos, J.L. Ras-like GTPases. Biochim. Biophys. Acta 1333:M19–31, 1997.
Wang, A., Yoshimi, N., Suzui, M., Yamauchi, A., Tarao, M., and Mori, H. Different expression patterns of cyclins A, D1, and E in human colorectal cancer. J. Cancer Res. Clin. Oncol. 122:122–126, 1996.
Kitahara, K., Yasui, W., Kuniyasu, H., et al. Concurrent amplification of cyclin E and cdk2 genes in colorectal carcinomas. Int. J. Cancer 62:25–28, 1995.
Arber, R, Hibshoosh, H., Moss, S.F., et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterol. 110:669–674, 1996.
DuBois, R.N., Shao, J., Tsujii, M., Sheng, H., and Beauchamp, R.D. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res. 56:733–737, 1996.
Hanif, R., Pittas, A., Feng, Y., et al. Effects of nonsteroidal antiinflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 52:237–245, 1996.
Elder, D.J.E., Hague, A., Hicks, D.J., and Paraskeva, C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res. 56:2273–2276, 1996.
Rigas, B. and Shiff, S.J. Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction. Med. Hypotheses submitted.
Rodrigues, N.R., Rowan, A., Smith, M.E., et al. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 87:7555–7559, 1990.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rigas, B., Shiff, S.J. (1999). Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Cyclooxygenases, and the Cell Cycle. In: Colon Cancer Prevention. Advances in Experimental Medicine and Biology, vol 470. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4149-3_13
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4149-3_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6861-8
Online ISBN: 978-1-4615-4149-3
eBook Packages: Springer Book Archive